OncoGenex Pharmaceuticals Inc. (NASDAQ:ACHV) posted its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, Bloomberg Earnings reports.
Shares of OncoGenex Pharmaceuticals (ACHV) traded down 1.99% during mid-day trading on Friday, hitting $2.95. The company’s stock had a trading volume of 14,038 shares. The company’s market cap is $8.07 million. The stock’s 50 day moving average price is $1.44 and its 200 day moving average price is $0.69. OncoGenex Pharmaceuticals has a 52-week low of $0.33 and a 52-week high of $4.85.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2017/08/19/oncogenex-pharmaceuticals-inc-nasdaqogxi-posts-quarterly-earnings-results-updated-updated.html.
Separately, ValuEngine upgraded OncoGenex Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 4th.
OncoGenex Pharmaceuticals Company Profile
Achieve Life Sciences, Inc, formerly OncoGenex Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States.
What are top analysts saying about OncoGenex Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for OncoGenex Pharmaceuticals Inc. and related companies.